These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6238932)

  • 21. Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
    Nakamura S; Nakata K; Katae H; Minami A; Kashimoto S; Yamagishi J; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 May; 23(5):742-9. PubMed ID: 6223579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.
    Hughes PJ; Webb DB; Asscher AW
    J Antimicrob Chemother; 1984 May; 13 Suppl B():55-7. PubMed ID: 6234276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of enoxacin and norfloxacin in patients with cystitis.
    Yamamoto M; Nagai T; Takaba H; Hashimoto J; Miyake K
    Hinyokika Kiyo; 1987 Dec; 33(12):2141-4. PubMed ID: 3482344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days.
    Tsuei SE; Darragh AS; Brick I
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():71-4. PubMed ID: 6389477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Norfloxacin disposition after sequentially increasing oral doses.
    Swanson BN; Boppana VK; Vlasses PH; Rotmensch HH; Ferguson RK
    Antimicrob Agents Chemother; 1983 Feb; 23(2):284-8. PubMed ID: 6220672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of quinoline carboxylic acid derivatives in the dog prostate.
    Jensen KM; Madsen PO
    Prostate; 1983; 4(4):407-14. PubMed ID: 6223287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enoxacin: a new fluoroquinolone.
    Jaber LA; Bailey EM; Rybak MJ
    Clin Pharm; 1989 Feb; 8(2):97-107. PubMed ID: 2645085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.
    Davies BI; Maesen FP; Teengs JP
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():83-9. PubMed ID: 6594325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.
    Eandi M; Viano I; Di Nola F; Leone L; Genazzani E
    Eur J Clin Microbiol; 1983 Jun; 2(3):253-9. PubMed ID: 6224683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Enoxacin--comparative pharmacokinetics and tissue penetration].
    Sörgel F; Naber KG; Metz R; Morgenroth A
    Infection; 1989; 17 Suppl 1():S14-8. PubMed ID: 2680989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.
    Muranaka K; Greenwood D
    J Antimicrob Chemother; 1988 May; 21(5):545-54. PubMed ID: 3134318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of enoxacin and norfloxacin on human colonic microflora.
    Edlund C; Lidbeck A; Kager L; Nord CE
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1846-8. PubMed ID: 3481249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
    Dobbs BR; Gazeley LR; Stewart IA; Edwards IR
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():61-6. PubMed ID: 3162903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens.
    Traub WH
    Chemotherapy; 1984; 30(6):379-86. PubMed ID: 6097410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():67-77. PubMed ID: 3162904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and tissue penetration of cefprozil.
    Nye K; O'Neill P; Andrews JM; Wise R
    J Antimicrob Chemother; 1990 May; 25(5):831-5. PubMed ID: 2373665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antichlamydial activity of quinolone carboxylic acids.
    Heppleston C; Richmond S; Bailey J
    J Antimicrob Chemother; 1985 May; 15(5):645-7. PubMed ID: 3159713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.